-
-
-
-
-
When it comes to treating lipids in patients with heart disease, the mantra may be, The lower the LDL, the better. Data from the multicenter Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial indicate that aggressive reduction of atherogenic lipoproteins prevents progression of disease.
-
Hormonal replacement therapy after breast canceris It Safe? (HABITS) began in May 1997, to compare breast cancer survivors treated for at least 2 years with hormone therapy with treatment other than hormones. By September 2003, a total of 434 women had been randomized and, in December 2003, the steering committee of the HABITS study made the decision to stop the trial because there were 26 women in the treated group and 7 in the non-treated group with new breast cancer diagnoses.
-
Changes in screening, endocervical sampling, nomenclature, and improvements in treatment likely explain the increased in situ cervical SCC incidence in white and black women. Increasing AIS incidence over the past 20 years in white women has not yet translated into a decrease in invasive AC incidence.
-
In this article, Adams and Nelson integrate results from several disparate fields to advance the concept that autoimmune conditions resemble host vs graft disease and that the graft in many cases may be fetal or maternal cells that lodge in the host, namely the mother or fetus, respectively.
-
The use of serum procalcitonin helps to differentiate bacterial from viral lower respiratory infections and may reduce the use of unnecessary antibiotics.
-
The common and increasing practice of opioid treatment for chronic pain is reviewed. Randomized trials support this therapy, however the risk benefit decision is complicated by new evidence of hazards making this practice more difficult.